AGC

AGC Invests $350M+ to Build Mammalian Plant in Japan: Boosting Biopharma Manufacturing

💰 AGC, a Japanese pharmaceutical company, plans to invest over $350 million in a new mammalian cell culture plant in Chiba, Japan. 🏭 This plant will produce cell cultures for biopharmaceutical manufacturing, strengthening AGC's position in the market. 🧪 Construction to be completed by 2022.